CLAIM #43553 · Merck & Company Inc (MRK) · 2025Q2 earnings call · Jul 29, 2025

“We remain committed to our dividend with the goal of increasing it over time.”

Caroline Litchfield · CFO

How to check this claim

Look at: Quarterly dividend per share declared by Merck

It came true if: Declared quarterly dividend per share higher than the rate in effect as of 2025-07-29

Where: Company dividend declarations (press releases / 10-Q filings)

Knowable after: 2026-07-29

In context

“nificantly lower in the second half of the year. While we actively manage the impact from foreign exchange through our revenue hedging program, based on mid-July rates, we expect to see a negative impact from our hedges, which is reflected in other revenue. Finally, we expect operating expenses to be roughly evenly split between the third and fourth quarters, excluding business development expenses. Now turning to capital allocation, where our strategy remains unchanged. We will prioritize investments in our business to drive near- and long-term growth. We will continue to invest in our innovative pipeline, including the initiation of many new late-stage clinical trials across multiple novel candidates, each of which has the potential to meaningfully address important unmet medical needs. We remain committed to our dividend with the goal of increasing it over time. Business development remains a high priority, as evidenced by our acquisition of Verona Pharma, which we expect to finance through a combination of cash on hand, commercial paper and new debt issuance. We maintain the ability within our strong investment-grade credit rating to pursue additional science-driven, value- enhancing transactions going forward. We continued our pace of share repurchases with approximately $1.3 billion in the quarter. We expect to maintain a similar level of repurchases in each of the third and fourth quarters of 2025, given our strong balance sheet. To conclude, we are confident in the outlook of our business driven by global demand for our innovative in-line portfolio and launches. We maintain our steadfast commitment to bringing forward medically significant i”

Verify independently

SEC filings for MRK ↗ · Quote is verbatim from the 2025Q2 earnings call.